•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D.
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Stock Picks From Seeking Alpha's September 2026 New Analysts
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?